|
1) Oka H, Tamori A, Kuroki T, et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994; 19: 61-6
|
|
|
|
2) Ishii M, Gama H, Chida N, et al. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol. 2000; 95: 1036-40
|
|
|
|
|
|
3) Okuda H, Nakanishi T, Takatsu K, et al. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer. 2000; 88: 544-9
|
|
|
|
|
4) Marrero JA, Su GL, Wei W, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology. 2003; 37: 1114-21
|
|
|
|
|
|
5) Ikoma J, Kaito M, Ishihara T, et al. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study. Hepatogastroenterology. 2002; 49: 235-8
|
|
|
|
|
|
6) Toyoda H, Kumada T, Kiriyama S, et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006; 4: 111-7
|
|
|
|
|
|
7) Nakamura S, Nouso K, Sakaguchi K, et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol. 2006; 101: 2038-43
|
|
|
|
|
|
8) Morra R, Munteanu M, Bedossa P, et al. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2007; 26: 847-58
|
|
|
|
|
|
9) Gangadharan B, Antrobus R, Dwek RA, et al. Serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem. 2007; 53: 1792-9
|
|
|
|
|
|
10) Nugent C, Younossi ZM. Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2007; 4: 432-41
|
|
|
|
|
|
11) Younossi ZM, Baranova A, Ziegler K, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology. 2005; 42: 665-74
|
|
|
|
|
|
12) Espina VA, Edmiston KH, Heiby M, et al. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics. 2008; 7: 1998-2018
|
|
|
|
|
|
13) Kriegsheim A, Preisinger C, Kolch W. Mapping of signaling pathways by functional interaction proteomics. Methods Mol Biol. 2008; 484: 177-92
|
|
|
|
|
|
14) Kuramitsu Y, Nakamura K. Proteomic analysis of cancer tissues: shedding light on carcinogenesis and possible biomarkers. Proteomics. 2006; 6: 5650-61
|
|
|
|
|
|
15) Lee IN, Chen CH, Sheu JC, et al. Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. J Proteome Res. 2005; 4: 2062-9
|
|
|
|
|
|
16) Melle C, Ernst G, Scheibner O, et al. Identification of specific protein markers in microdissected hepatocellular carcinoma. J Proteome Res. 2007; 6: 306-15
|
|
|
|
|
|
17) Tiss A, Smith C, Camuzeaux S, et al. Serum peptide profiling using MALDI mass spectrometry: avoiding the pitfalls of coated magnetic beads using well-established ZipTip technology. Proteomics. 2007; 7 Suppl 1: 77-89
|
|
|
|
|
|
18) Shoshan SH, Admon A. Novel technologies for cancer biomarker discovery: humoral proteomics. Cancer Biomark. 2007; 3: 141-52
|
|
|
|
|
|
19) Yang MH, Tyan YC, Jong SB, et al. Identification of human hepatocellular carcinoma-related proteins by proteomic approaches. Anal Bioanal Chem. 2007; 388: 637-43
|
|
|
|
|
|
20) Ang IL, Poon TC, Lai PB, et al. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach. J Proteome Res. 2006; 5: 2691-700
|
|
|
|
|
|
21) Feng JT, Liu YK, Song HY, et al. Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics. 2005; 5: 4581-8
|
|
|
|
|
|
22) Zinkin NT, Grall F, Bhaskar K, et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res. 2008; 14: 470-7
|
|
|
|
|
|
23) He QY, Zhu R, Lei T, et al. Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma. J Cell Biochem. 2008; 103: 740-52
|
|
|
|
|
|
24) Kanmura S, Uto H, Kusumoto K, et al. Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip System. Hepatology. 2007; 45: 948-56
|
|
|
|
|
|
25) Cui J, Kang X, Dai Z, et al. Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification. J Cancer Res Clin Oncol. 2007; 133: 825-34
|
|
|
|
|
|
26) Gobel T, Vorderwulbecke S, Hauck K, et al. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J Gastroenterol. 2006; 12: 7604-12
|
|
|
|
|
|
27) Ward DG, Cheng Y, N'Kontchou G, et al. Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br J Can. 2006; 94: 287-93
|
|
|
|
|
|
28) Lee IN Chen CH, Sheu JC, et al. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics. 2006; 6: 2865-73
|
|
|
|
|
|
29) Geng X, Wang F, Li YG, at al. SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma. J Exp Clin Cancer Res. 2007; 26: 505-8
|
|
|
|
|
|
30) He M, Qin J, Ahai R, et al. Detection and identification of NAP-2 as biomarker in hepatitis B-related hepatocellular carcinoma by proteomic approach. Proteome Science. 2008; 6: 10
|
|
|
|
|
|
31) Ward DG, Cheng Y, N'Kontchou G, et al. Preclinical and post-treatment changes in the HCC-associated serum proteome. Br J Cancer. 2006; 95: 1379-83
|
|
|
|
|
|
32) Poon TCW, Hui A, Chan HLY, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: A pilot study. Clinical Chemistry. 2005; 51: 328-35
|
|
|
|
|
|
33) Van Greevenbroek MM, Vermeulen VM, De Bruin TW. Identification of novel molecular candidates for fatty liver in the hyperlipidemic mouse model, HcB19. J Lipid Res. 2004; 45: 1148-54
|
|
|
|
|
|
34) Uto H, Sato Y, Ishida Y, et al. Proteomic analysis of serum biomarkers in patients with nonalcoholic steatohepatitis using SELDI-TOF/MS or MALDI-TOF/MS. Hepatology. 2007; 46 (Supple): 735A
|
|
|
|
|
|
35) Orvisky E, Drake SK, Martin BM, et al. Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma. Proteomics. 2006; 6: 2895-902
|
|
|
|
|
|
36) Goldmann R, Ressom HW, Abdel-Hamid M, et al. Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum. Carcinogenesis. 2007; 28(10); 2149-53
|
|
|
|
|
|
37) Kam RKT, Poon TCW, Chan HLY, et al. High-throughput quantitative profiling of serum N-glycome by MALDI-TOF mass spectorometry and N-glycomic fingerprint of liver fibrosis. Clinical Chemistry. 2007; 53: 1254-63
|
|
|
|
|
|
38) Resson HW, Varghese RS, Goldman L, et al. Analysis of MALDI-TOF mass spectrometry deta for discovery of peptide and glycan biomarkers of hepatocellular carcinoma. J Proteome Res. 2008; 7: 603-10
|
|
|
|
|
|
39) Comunale MA, Lowman M, Long RE, et al. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res. 2006; 5: 308-15
|
|
|
|
|
|
40) Paradis V, Asselah T, Dargere D, et al. Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin. Gastroenterology. 2006; 130: 2189-97
|
|
|
|
|
|
41) Miyazaki T, Ohura T, Kobayashi M, et al. Fatal propionic acidemia in mice lacking propionyl-CoA carboxylase and its rescue by postnatal, liver-specific supplementation via a transgene. J Biol Chem. 2001; 276: 35995-9
|
|
|
|
|
|
42) Seimiya M, Tomonaga T, Matsushita K, et al. Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and formiminotransferase cyclodeaminase. Hepatology. 2008; 48: 519-30
|
|
|
|
|
|
43) Orimo T, Ojima H, Hiraoka N, et al. Proteomic profiling reveals the prognostic value of APC-binding protein EB1 in hepatocellular carcinoma. Hepatology. 2008(in press)
|
|
|
|
|